EUVIMEDEUVIMED entdecken
Leitlinie

Prescribing in borderline personality disorder – the clinical guidelines

Devender Yadav

Progress in Neurology and Psychiatry · 2020-04 · 24 (2) · 25-30

DOI: 10.1002/pnp.667 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Progress in Neurology and Psychiatry, online erschienen am 15.05.2020. Verfasst von Devender Yadav. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug prescription and polypharmacy are commonly seen in the management of borderline personality disorder (BPD) in clinical practice, and the ‘placebo effect of medications’ in BPD patients is significant. However, it is to be noted that ‘no drug’ has a UK market authorisation or Food & Drug Administration approval in the USA for BPD. Here Dr Yadav reviews the guidelines.

Zitieren

APA

Yadav, D. (2020). Prescribing in borderline personality disorder – the clinical guidelines. Progress in Neurology and Psychiatry, 24(2), 25-30. https://doi.org/10.1002/pnp.667

Vancouver

Yadav D. Prescribing in borderline personality disorder – the clinical guidelines. Progress in Neurology and Psychiatry. 2020;24(2):25-30. doi:10.1002/pnp.667

BibTeX
@article{Yadav2020,
  author = {Yadav, Devender},
  title = {Prescribing in borderline personality disorder – the clinical guidelines},
  journal = {Progress in Neurology and Psychiatry},
  year = {2020},
  volume = {24},
  number = {2},
  pages = {25--30},
  doi = {10.1002/pnp.667}
}
Kostenlos starten →